Notice of Amendment, 78981-78983 [2022-28010]
Download as PDF
Federal Register / Vol. 87, No. 246 / Friday, December 23, 2022 / Notices
Program (CICP) to provide benefits to
certain individuals or estates of
individuals who sustain a serious
physical covered injury as the direct
result of the administration or use of the
Covered Countermeasures and/or
benefits to certain survivors of
individuals who die as a direct result of
the administration or use of the Covered
Countermeasures. The causal
connection between the countermeasure
and the serious physical injury must be
supported by compelling, reliable, valid,
medical, and scientific evidence in
order for the individual to be considered
for compensation. The CICP is
administered by the Health Resources
and Services Administration, within the
Department of Health and Human
Services. Information about the CICP is
available at the toll-free number 1–855–
266–2427 or https://www.hrsa.gov
/cicp/.
TKELLEY on DSK125TN23PROD with NOTICE
XV. Amendments
20:36 Dec 22, 2022
Xavier Becerra,
Secretary of Health and Human Services.
[FR Doc. 2022–28014 Filed 12–22–22; 8:45 am]
BILLING CODE 4150–37–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Office of the Secretary
Notice of Amendment
ACTION:
Notice of amendment.
The Secretary is amending the
Declaration issued in the Federal
Register of October 1, 2008, and as
amended and republished January 1,
2016, pursuant to section 319F–3 of the
Public Health Service Act, to extend the
effective time period of the Republished
Declaration, as amended.
DATES: This amendment of the January
1, 2016, Republished Declaration is
effective January 1, 2023.
FOR FURTHER INFORMATION CONTACT: L.
Paige Ezernack, Administration for
Strategic Preparedness and Response,
Department of Health and Human
Services, 200 Independence Avenue
SW, Washington, DC 20201; 202–260–
0365, paige.ezernack@hhs.gov.
SUPPLEMENTARY INFORMATION: The
Public Readiness and Emergency
Preparedness Act (PREP Act) authorizes
the Secretary of Health and Human
Services (the Secretary) to issue a
Declaration to provide liability
immunity to certain individuals and
entities (Covered Persons) against any
claim of loss caused by, arising out of,
relating to, or resulting from the
administration or use of medical
countermeasures (Covered
Countermeasures), except for claims
that meet the PREP Act’s definition of
willful misconduct. The Secretary may,
through publication in the Federal
Register, amend any portion of a
Declaration.
The PREP Act was enacted on
December 30, 2005, as Public Law 109–
148, Division C, Section 2. It amended
the Public Health Service (PHS) Act,
adding section 319F–3, which addresses
liability immunity, and section 319F–4,
which creates a compensation program.
These sections are codified in the U.S.
SUMMARY:
42 U.S.C. 247d–6d(b)(4)
The October 10, 2008, Declaration
Under the Public Readiness and
Emergency Preparedness Act for
pandemic influenza antivirals was first
published on October 17, 2008, and
amended effective April 26, 2009.
The December 17, 2008, Declaration
Under the Public Readiness and
Emergency Preparedness Act for
diagnostics and other devices was first
published on December 22, 2008.
The Declaration for the Use of the
Public Readiness and Emergency
Preparedness Act for H5N1 vaccines
was first published on January 26, 2007.
The Declaration was amended on
November 30, 2007, to add H7 and H9
vaccines; amended on October 17, 2008,
to add H2 and H6 vaccines; amended on
June 15, 2009, to add 2009 H1N1
vaccines and republished in its entirety;
amended on September 28, 2009, to
provide targeted liability protections for
pandemic countermeasures to enhance
distribution and to add provisions
consistent with other Declarations and
republished in its entirety; amended on
March 1, 2010, to revise the Covered
Countermeasures to include
countermeasures against pandemic
influenza A viruses, extend the effective
date and republished in its entirety; and
amended on February 29, 2012, to
extend the effective time period,
reformat the Declaration, and republish
the Declaration.
The January 1, 2016, Republished
Declaration Under the Public Readiness
and Emergency Preparedness Act
amended all Declarations and
amendments prior to the date of its
publication in the Federal Register and
VerDate Sep<11>2014
republished the prior Declarations in
the Federal Register as a single
Declaration in its entirety, as amended.
This Declaration republishes the
January 1, 2016 Declaration to extend
the effect time period. Further
amendments to this Declaration will be
published in the Federal Register.
Authority: 42 U.S.C. 247d–6d.
Jkt 259001
PO 00000
Frm 00069
Fmt 4703
Sfmt 4703
78981
Code as 42 U.S.C. 247d–6d and 42
U.S.C. 247d–6e, respectively. Section
319F–3 of the PHS Act has been
amended by the Pandemic and AllHazards Preparedness Reauthorization
Act (PAHPRA), Public Law 113–5,
enacted on March 13, 2013, and the
Coronavirus Aid, Relief, and Economic
Security (CARES) Act, Public Law 116–
136, enacted on March 27, 2020, to
expand Covered Countermeasures under
the PREP Act. The Secretary is now
amending the Republished Declaration
to extend the time period for which
liability immunity is in effect for all of
the Covered Countermeasures to
December 31, 2027.
Renewal of the PREP Act Declaration
for anthrax is essential due to the
continued national security threat posed
by potential exposure to anthrax. An
anthrax event, whether natural or manmade in origin, has potential to cause
significant mortality and disrupt daily
functions within the United States.
PREP Act coverage of countermeasures
is critical to the engagement with
potential product sponsors in the
anthrax space. Vaccines, antibiotics,
antitoxins, and diagnostics for anthrax
will continue to be a part of the
preparedness posture in terms of
stockpiling current products and
development next-generation
candidates. Extension of the PREP Act
Declaration including vaccines,
therapeutics, and diagnostics for
anthrax is therefore deemed essential.
Unless otherwise noted, all statutory
citations below are to the U.S. Code.
Republished Declaration
Declaration, as Amended, for Public
Readiness and Emergency Preparedness
Act Coverage for Anthrax
Countermeasures.
This Declaration amends the January
1, 2016, Republished Declaration under
the Public Readiness and Emergency
Preparedness Act. To the extent any
term of the prior Declaration is
inconsistent with any provision of this
Republished Declaration, the terms of
this Republished Declaration are
controlling.
I. Determination of Public Health
Emergency or Credible Risk of Future
Public Health Emergency
42 U.S.C. 247d–6d(b)(1)
I have determined that there is a
credible risk that the spread of Bacillus
anthracis and/or the spores of Bacillus
anthracis and the resulting disease or
conditions may in the future constitute
a public health emergency.
E:\FR\FM\23DEN1.SGM
23DEN1
78982
Federal Register / Vol. 87, No. 246 / Friday, December 23, 2022 / Notices
II. Factors Considered
VI. Covered Countermeasures
42 U.S.C. 247d–6d(b)(6)
IV. Liability Immunity
42 U.S.C. 247d–6b(c)(1)(B), 42 U.S.C.
247d–6d(i)(1) and (7)
Covered Countermeasures are any
vaccine, including all components and
constituent materials of these vaccines,
and all devices and their constituent
components used in the administration
of these vaccines; any antimicrobial/
antibiotic; any other drug or biologic; or
any diagnostic or other device to
identify, prevent, or treat anthrax or
adverse events from such
countermeasures.
Covered Countermeasures must be
‘‘qualified pandemic or epidemic
products,’’ or ‘‘security
countermeasures,’’ or drugs, biological
products, or devices authorized for
investigational or emergency use, as
those terms are defined in the PREP Act,
the FD&C Act, and the PHS Act.
42 U.S.C. 247d–6d(a), 247d–6d(b)(1)
VII. Limitations on Distribution
Liability immunity as prescribed in
the Public Readiness and Emergency
Preparedness (PREP) Act and conditions
stated in this Declaration is in effect for
the Recommended Activities described
in Section III.
42 U.S.C. 247d–6d(a)(5) and (b)(2)(E)
I have determined that liability
immunity is afforded to Covered
Persons only for Recommended
Activities involving Covered
Countermeasures that are related to:
(a) Present or future Federal contracts,
cooperative agreements, grants, other
transactions, interagency agreements,
memoranda of understanding, or other
Federal agreements, or activities directly
conducted by the Federal Government;
or
(b) Activities authorized in
accordance with the public health and
medical response of the Authority
Having Jurisdiction to prescribe,
administer, deliver, distribute, or
dispense the Covered Countermeasures
following a declaration of an emergency.
i. The Authority Having Jurisdiction
means the public agency or its delegate
that has legal responsibility and
authority for responding to an incident,
based on political or geographical (e.g.,
city, county, tribal, state, or Federal
boundary lines) or functional (e.g., law
enforcement, public health) range or
sphere of authority.
ii. A declaration of emergency means
any declaration by any authorized local,
regional, state, or Federal official of an
emergency specific to events that
indicate an immediate need to
administer and use the Covered
Countermeasures, with the exception of
a Federal Declaration in support of an
Emergency Use Authorization under
section 564 of the FD&C Act unless such
Declaration specifies otherwise.
I have also determined that for
governmental program planners only,
liability immunity is afforded only to
I have considered the desirability of
encouraging the design, development,
clinical testing or investigation,
manufacture, labeling, distribution,
formulation, packaging, marketing,
promotion, sale, purchase, donation,
dispensing, prescribing, administration,
licensing, and use of the Covered
Countermeasures.
III. Recommended Activities
42 U.S.C. 247d–6d(b)(1)
I recommend, under the conditions
stated in this Declaration, the
manufacture, testing, development,
distribution, administration, or use of
the Covered Countermeasures.
V. Covered Persons
TKELLEY on DSK125TN23PROD with NOTICE
42 U.S.C. 247d–6d(i)(2), (3), (4), (6),
(8)(A) and (B)
Covered Persons who are afforded
liability immunity under this
Declaration are manufacturers,
distributors, program planners,
‘‘qualified persons,’’ and their officials,
agents, and employees, as those terms
are defined in the PREP Act, and the
United States.
In addition, I have determined that
the following additional persons are
qualified persons: (a) Any person
authorized in accordance with the
public health and medical emergency
response of the Authority Having
Jurisdiction, as described in section VII
below, to prescribe, administer, deliver,
distribute or dispense the Covered
Countermeasures, and their officials,
agents, employees, contractors and
volunteers, following a declaration of an
emergency; (b) Any person authorized
to prescribe, administer, or dispense the
Covered Countermeasures or who is
otherwise authorized to perform an
activity under an Emergency Use
Authorization in accordance with
section 564 of the Federal Food, Drug,
and Cosmetic Act (FD&C Act); and (c)
Any person authorized to prescribe,
administer, or dispense Covered
Countermeasures in accordance with
section 564A of the FD&C Act.
VerDate Sep<11>2014
20:36 Dec 22, 2022
Jkt 259001
PO 00000
Frm 00070
Fmt 4703
Sfmt 4703
the extent such program planners obtain
Covered Countermeasures through
voluntary means, such as (1) donation;
(2) commercial sale; (3) deployment of
Covered Countermeasures from Federal
stockpiles; or (4) deployment of
donated, purchased, or otherwise
voluntarily obtained Covered
Countermeasures from state, local, or
private stockpiles.
VIII. Category of Disease, Health
Condition, or Threat
42 U.S.C. 247d–6d(b)(2)(A)
The category of disease, health
condition, or threat for which I
recommend the administration or use of
the Covered Countermeasures is
anthrax, which may result from
exposure to Bacillus anthracis and/or to
Bacillus anthracis spores.
IX. Administration of Covered
Countermeasures
42 U.S.C. 247d–6d(a)(2)(B)
Administration of the Covered
Countermeasures means physical
provision of the countermeasures to
recipients, or activities and decisions
directly relating to public and private
delivery, distribution, and dispensing of
the countermeasures to recipients,
management and operation of
countermeasure programs, or
management and operation of locations
for the purpose of distributing and
dispensing countermeasures.
X. Population
42 U.S.C. 247d–6d(a)(4), 247d–
6d(b)(2)(C)
The populations of individuals
include any individual who uses or is
administered the Covered
Countermeasures in accordance with
this Declaration.
Liability immunity is afforded to
manufacturers and distributors without
regard to whether the countermeasure is
used by or administered to this
population; liability immunity is
afforded to program planners and
qualified persons when the
countermeasure is used by or
administered to this population, or the
program planner or qualified person
reasonably could have believed the
recipient was in this population.
XI. Geographic Area
42 U.S.C. 247d–6d(a)(4), 247d–
6d(b)(2)(D)
Liability immunity is afforded for the
administration or use of a Covered
Countermeasure without geographic
limitation.
E:\FR\FM\23DEN1.SGM
23DEN1
Federal Register / Vol. 87, No. 246 / Friday, December 23, 2022 / Notices
Liability immunity is afforded to
manufacturers and distributors without
regard to whether the countermeasure is
used by or administered in these
geographic areas; liability immunity is
afforded to program planners and
qualified persons when the
countermeasure is used by or
administered in these geographic areas,
or the program planner or qualified
person reasonably could have believed
the recipient was in these geographic
areas.
XII. Effective Time Period
42 U.S.C. 247d–6d(b)(2)(B)
Liability immunity for Covered
Countermeasures obtained through
means of distribution other than in
accordance with the public health and
medical response of the Authority
Having Jurisdiction extends through
December 31, 2027.
Liability immunity for Covered
Countermeasures administered and
used in accordance with the public
health and medical response of the
Authority Having Jurisdiction begins
with a Declaration and lasts through (1)
the final day the emergency Declaration
is in effect or (2) December 31, 2027,
whichever occurs first.
TKELLEY on DSK125TN23PROD with NOTICE
XIII. Additional Time Period of
Coverage
42 U.S.C. 247d–6d(b)(3)(B) and (C)
I have determined that an additional
twelve (12) months of liability
protection is reasonable to allow for the
manufacturer(s) to arrange for
disposition of the Covered
Countermeasures, including return of
the Covered Countermeasures to the
manufacturer, and for Covered Persons
to take other appropriate actions to limit
the administration or use of the Covered
Countermeasures.
Covered Countermeasures obtained
for the Strategic National Stockpile
(SNS) during the effective period of this
Declaration for Covered
Countermeasures obtained through
means of distribution other than in
accordance with the public health and
medical response of the Authority
Having Jurisdiction are covered through
the date of administration or use
pursuant to a distribution or release
from the SNS.
Further, as to doses shipped by the
Centers for Disease Control and
Prevention (CDC) to the Department of
Defense (DoD) pursuant to the DoD/CDC
Interagency Agreement (IAA) dated
March 10, 2008, an additional period of
time of liability protection shall extend
for as long as the SNS or its successor
exists and the IAA remains in effect,
VerDate Sep<11>2014
20:36 Dec 22, 2022
Jkt 259001
plus, if the additional twelve (12)
months following the time period in
paragraph 1 of this section has expired,
an additional twelve (12) months upon
expiration of the IAA.
XIV. Countermeasures Injury
Compensation Program
42 U.S.C. 247d–6e
The PREP Act authorizes the
Countermeasures Injury Compensation
Program (CICP) to provide benefits to
certain individuals or estates of
individuals who sustain a serious
physical covered injury as the direct
result of the administration or use of the
Covered Countermeasures and/or
benefits to certain survivors of
individuals who die as a direct result of
the administration or use of the Covered
Countermeasures. The causal
connection between the countermeasure
and the serious physical injury must be
supported by compelling, reliable, valid,
medical, and scientific evidence in
order for the individual to be considered
for compensation. The CICP is
administered by the Health Resources
and Services Administration, within the
Department of Health and Human
Services. Information about the CICP is
available at the toll-free number 1–855–
266–2427 or https://www.hrsa.gov
/cicp/.
XV. Amendments
42 U.S.C. 247d–6d(b)(4)
The October 1, 2008, Declaration
Under the Public Readiness and
Emergency Preparedness Act for
Anthrax Countermeasures was first
published on October 6, 2008, and
amended and republished on January 1,
2016. This is the second amendment to
the Declaration.
Further amendments to this
Declaration will be published in the
Federal Register.
Authority: 42 U.S.C. 247d–6d.
Xavier Becerra,
Secretary of Health and Human Services.
[FR Doc. 2022–28010 Filed 12–22–22; 8:45 am]
BILLING CODE 4150–37–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Office of the Secretary
Notice of Amendment
ACTION:
Notice of amendment.
The Secretary is amending the
Declaration issued in the Federal
Register of October 10, 2008, and as
amended and republished January 1,
SUMMARY:
PO 00000
Frm 00071
Fmt 4703
Sfmt 4703
78983
2016, pursuant to section 319F–3 of the
Public Health Service Act, to extend the
effective time period of the Republished
Declaration, as amended.
DATES: This Amendment of the January
1, 2016, Republished Declaration is
effective January 1, 2023.
FOR FURTHER INFORMATION CONTACT: L.
Paige Ezernack, Administration for
Strategic Preparedness and Response,
Department of Health and Human
Services, 200 Independence Avenue
SW, Washington, DC 20201; 202–260–
0365, paige.ezernack@hhs.gov.
SUPPLEMENTARY INFORMATION: The
Public Readiness and Emergency
Preparedness Act (PREP Act) authorizes
the Secretary of Health and Human
Services (the Secretary) to issue a
Declaration to provide liability
immunity to certain individuals and
entities (Covered Persons) against any
claim of loss caused by, arising out of,
relating to, or resulting from the
administration or use of medical
countermeasures (Covered
Countermeasures), except for claims
that meet the PREP Act’s definition of
willful misconduct. The Secretary may,
through publication in the Federal
Register, amend any portion of a
Declaration.
The PREP Act was enacted on
December 30, 2005, as Public Law 109–
148, Division C, Section 2. It amended
the Public Health Service (PHS) Act,
adding Section 319F–3, which
addresses liability immunity, and
Section 319F–4, which creates a
compensation program. These sections
are codified in the U.S. Code as 42
U.S.C. 247d–6d and 42 U.S.C. 247d–6e,
respectively. Section 319F–3 of the PHS
Act has been amended by the Pandemic
and All-Hazards Preparedness
Reauthorization Act (PAHPRA), Public
Law 113–5, enacted on March 13, 2013,
and the Coronavirus Aid, Relief, and
Economic Security (CARES) Act, Public
Law 116–136, enacted on March 27,
2020, to expand Covered
Countermeasures under the PREP Act.
The Secretary is now amending the
Republished Declaration to extend the
time period for which liability
immunity is in effect for all of the
Covered Countermeasures to December
31, 2027. Botulinum Toxin continues to
pose a national security threat to the
United States and has the potential to
cause significant morbidity and
mortality in the event of large-scale
exposures. There is a lack of a
commercial market for countermeasures
against Botulinum Toxin, making PREP
Act coverage critical to the engagement
with potential product sponsors.
Vaccines, therapeutics, and diagnostics
E:\FR\FM\23DEN1.SGM
23DEN1
Agencies
[Federal Register Volume 87, Number 246 (Friday, December 23, 2022)]
[Notices]
[Pages 78981-78983]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2022-28010]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Office of the Secretary
Notice of Amendment
ACTION: Notice of amendment.
-----------------------------------------------------------------------
SUMMARY: The Secretary is amending the Declaration issued in the
Federal Register of October 1, 2008, and as amended and republished
January 1, 2016, pursuant to section 319F-3 of the Public Health
Service Act, to extend the effective time period of the Republished
Declaration, as amended.
DATES: This amendment of the January 1, 2016, Republished Declaration
is effective January 1, 2023.
FOR FURTHER INFORMATION CONTACT: L. Paige Ezernack, Administration for
Strategic Preparedness and Response, Department of Health and Human
Services, 200 Independence Avenue SW, Washington, DC 20201; 202-260-
0365, [email protected].
SUPPLEMENTARY INFORMATION: The Public Readiness and Emergency
Preparedness Act (PREP Act) authorizes the Secretary of Health and
Human Services (the Secretary) to issue a Declaration to provide
liability immunity to certain individuals and entities (Covered
Persons) against any claim of loss caused by, arising out of, relating
to, or resulting from the administration or use of medical
countermeasures (Covered Countermeasures), except for claims that meet
the PREP Act's definition of willful misconduct. The Secretary may,
through publication in the Federal Register, amend any portion of a
Declaration.
The PREP Act was enacted on December 30, 2005, as Public Law 109-
148, Division C, Section 2. It amended the Public Health Service (PHS)
Act, adding section 319F-3, which addresses liability immunity, and
section 319F-4, which creates a compensation program. These sections
are codified in the U.S. Code as 42 U.S.C. 247d-6d and 42 U.S.C. 247d-
6e, respectively. Section 319F-3 of the PHS Act has been amended by the
Pandemic and All-Hazards Preparedness Reauthorization Act (PAHPRA),
Public Law 113-5, enacted on March 13, 2013, and the Coronavirus Aid,
Relief, and Economic Security (CARES) Act, Public Law 116-136, enacted
on March 27, 2020, to expand Covered Countermeasures under the PREP
Act. The Secretary is now amending the Republished Declaration to
extend the time period for which liability immunity is in effect for
all of the Covered Countermeasures to December 31, 2027.
Renewal of the PREP Act Declaration for anthrax is essential due to
the continued national security threat posed by potential exposure to
anthrax. An anthrax event, whether natural or man-made in origin, has
potential to cause significant mortality and disrupt daily functions
within the United States. PREP Act coverage of countermeasures is
critical to the engagement with potential product sponsors in the
anthrax space. Vaccines, antibiotics, antitoxins, and diagnostics for
anthrax will continue to be a part of the preparedness posture in terms
of stockpiling current products and development next-generation
candidates. Extension of the PREP Act Declaration including vaccines,
therapeutics, and diagnostics for anthrax is therefore deemed
essential.
Unless otherwise noted, all statutory citations below are to the
U.S. Code.
Republished Declaration
Declaration, as Amended, for Public Readiness and Emergency
Preparedness Act Coverage for Anthrax Countermeasures.
This Declaration amends the January 1, 2016, Republished
Declaration under the Public Readiness and Emergency Preparedness Act.
To the extent any term of the prior Declaration is inconsistent with
any provision of this Republished Declaration, the terms of this
Republished Declaration are controlling.
I. Determination of Public Health Emergency or Credible Risk of Future
Public Health Emergency
42 U.S.C. 247d-6d(b)(1)
I have determined that there is a credible risk that the spread of
Bacillus anthracis and/or the spores of Bacillus anthracis and the
resulting disease or conditions may in the future constitute a public
health emergency.
[[Page 78982]]
II. Factors Considered
42 U.S.C. 247d-6d(b)(6)
I have considered the desirability of encouraging the design,
development, clinical testing or investigation, manufacture, labeling,
distribution, formulation, packaging, marketing, promotion, sale,
purchase, donation, dispensing, prescribing, administration, licensing,
and use of the Covered Countermeasures.
III. Recommended Activities
42 U.S.C. 247d-6d(b)(1)
I recommend, under the conditions stated in this Declaration, the
manufacture, testing, development, distribution, administration, or use
of the Covered Countermeasures.
IV. Liability Immunity
42 U.S.C. 247d-6d(a), 247d-6d(b)(1)
Liability immunity as prescribed in the Public Readiness and
Emergency Preparedness (PREP) Act and conditions stated in this
Declaration is in effect for the Recommended Activities described in
Section III.
V. Covered Persons
42 U.S.C. 247d-6d(i)(2), (3), (4), (6), (8)(A) and (B)
Covered Persons who are afforded liability immunity under this
Declaration are manufacturers, distributors, program planners,
``qualified persons,'' and their officials, agents, and employees, as
those terms are defined in the PREP Act, and the United States.
In addition, I have determined that the following additional
persons are qualified persons: (a) Any person authorized in accordance
with the public health and medical emergency response of the Authority
Having Jurisdiction, as described in section VII below, to prescribe,
administer, deliver, distribute or dispense the Covered
Countermeasures, and their officials, agents, employees, contractors
and volunteers, following a declaration of an emergency; (b) Any person
authorized to prescribe, administer, or dispense the Covered
Countermeasures or who is otherwise authorized to perform an activity
under an Emergency Use Authorization in accordance with section 564 of
the Federal Food, Drug, and Cosmetic Act (FD&C Act); and (c) Any person
authorized to prescribe, administer, or dispense Covered
Countermeasures in accordance with section 564A of the FD&C Act.
VI. Covered Countermeasures
42 U.S.C. 247d-6b(c)(1)(B), 42 U.S.C. 247d-6d(i)(1) and (7)
Covered Countermeasures are any vaccine, including all components
and constituent materials of these vaccines, and all devices and their
constituent components used in the administration of these vaccines;
any antimicrobial/antibiotic; any other drug or biologic; or any
diagnostic or other device to identify, prevent, or treat anthrax or
adverse events from such countermeasures.
Covered Countermeasures must be ``qualified pandemic or epidemic
products,'' or ``security countermeasures,'' or drugs, biological
products, or devices authorized for investigational or emergency use,
as those terms are defined in the PREP Act, the FD&C Act, and the PHS
Act.
VII. Limitations on Distribution
42 U.S.C. 247d-6d(a)(5) and (b)(2)(E)
I have determined that liability immunity is afforded to Covered
Persons only for Recommended Activities involving Covered
Countermeasures that are related to:
(a) Present or future Federal contracts, cooperative agreements,
grants, other transactions, interagency agreements, memoranda of
understanding, or other Federal agreements, or activities directly
conducted by the Federal Government;
or
(b) Activities authorized in accordance with the public health and
medical response of the Authority Having Jurisdiction to prescribe,
administer, deliver, distribute, or dispense the Covered
Countermeasures following a declaration of an emergency.
i. The Authority Having Jurisdiction means the public agency or its
delegate that has legal responsibility and authority for responding to
an incident, based on political or geographical (e.g., city, county,
tribal, state, or Federal boundary lines) or functional (e.g., law
enforcement, public health) range or sphere of authority.
ii. A declaration of emergency means any declaration by any
authorized local, regional, state, or Federal official of an emergency
specific to events that indicate an immediate need to administer and
use the Covered Countermeasures, with the exception of a Federal
Declaration in support of an Emergency Use Authorization under section
564 of the FD&C Act unless such Declaration specifies otherwise.
I have also determined that for governmental program planners only,
liability immunity is afforded only to the extent such program planners
obtain Covered Countermeasures through voluntary means, such as (1)
donation; (2) commercial sale; (3) deployment of Covered
Countermeasures from Federal stockpiles; or (4) deployment of donated,
purchased, or otherwise voluntarily obtained Covered Countermeasures
from state, local, or private stockpiles.
VIII. Category of Disease, Health Condition, or Threat
42 U.S.C. 247d-6d(b)(2)(A)
The category of disease, health condition, or threat for which I
recommend the administration or use of the Covered Countermeasures is
anthrax, which may result from exposure to Bacillus anthracis and/or to
Bacillus anthracis spores.
IX. Administration of Covered Countermeasures
42 U.S.C. 247d-6d(a)(2)(B)
Administration of the Covered Countermeasures means physical
provision of the countermeasures to recipients, or activities and
decisions directly relating to public and private delivery,
distribution, and dispensing of the countermeasures to recipients,
management and operation of countermeasure programs, or management and
operation of locations for the purpose of distributing and dispensing
countermeasures.
X. Population
42 U.S.C. 247d-6d(a)(4), 247d-6d(b)(2)(C)
The populations of individuals include any individual who uses or
is administered the Covered Countermeasures in accordance with this
Declaration.
Liability immunity is afforded to manufacturers and distributors
without regard to whether the countermeasure is used by or administered
to this population; liability immunity is afforded to program planners
and qualified persons when the countermeasure is used by or
administered to this population, or the program planner or qualified
person reasonably could have believed the recipient was in this
population.
XI. Geographic Area
42 U.S.C. 247d-6d(a)(4), 247d-6d(b)(2)(D)
Liability immunity is afforded for the administration or use of a
Covered Countermeasure without geographic limitation.
[[Page 78983]]
Liability immunity is afforded to manufacturers and distributors
without regard to whether the countermeasure is used by or administered
in these geographic areas; liability immunity is afforded to program
planners and qualified persons when the countermeasure is used by or
administered in these geographic areas, or the program planner or
qualified person reasonably could have believed the recipient was in
these geographic areas.
XII. Effective Time Period
42 U.S.C. 247d-6d(b)(2)(B)
Liability immunity for Covered Countermeasures obtained through
means of distribution other than in accordance with the public health
and medical response of the Authority Having Jurisdiction extends
through December 31, 2027.
Liability immunity for Covered Countermeasures administered and
used in accordance with the public health and medical response of the
Authority Having Jurisdiction begins with a Declaration and lasts
through (1) the final day the emergency Declaration is in effect or (2)
December 31, 2027, whichever occurs first.
XIII. Additional Time Period of Coverage
42 U.S.C. 247d-6d(b)(3)(B) and (C)
I have determined that an additional twelve (12) months of
liability protection is reasonable to allow for the manufacturer(s) to
arrange for disposition of the Covered Countermeasures, including
return of the Covered Countermeasures to the manufacturer, and for
Covered Persons to take other appropriate actions to limit the
administration or use of the Covered Countermeasures.
Covered Countermeasures obtained for the Strategic National
Stockpile (SNS) during the effective period of this Declaration for
Covered Countermeasures obtained through means of distribution other
than in accordance with the public health and medical response of the
Authority Having Jurisdiction are covered through the date of
administration or use pursuant to a distribution or release from the
SNS.
Further, as to doses shipped by the Centers for Disease Control and
Prevention (CDC) to the Department of Defense (DoD) pursuant to the
DoD/CDC Interagency Agreement (IAA) dated March 10, 2008, an additional
period of time of liability protection shall extend for as long as the
SNS or its successor exists and the IAA remains in effect, plus, if the
additional twelve (12) months following the time period in paragraph 1
of this section has expired, an additional twelve (12) months upon
expiration of the IAA.
XIV. Countermeasures Injury Compensation Program
42 U.S.C. 247d-6e
The PREP Act authorizes the Countermeasures Injury Compensation
Program (CICP) to provide benefits to certain individuals or estates of
individuals who sustain a serious physical covered injury as the direct
result of the administration or use of the Covered Countermeasures and/
or benefits to certain survivors of individuals who die as a direct
result of the administration or use of the Covered Countermeasures. The
causal connection between the countermeasure and the serious physical
injury must be supported by compelling, reliable, valid, medical, and
scientific evidence in order for the individual to be considered for
compensation. The CICP is administered by the Health Resources and
Services Administration, within the Department of Health and Human
Services. Information about the CICP is available at the toll-free
number 1-855-266-2427 or https://www.hrsa.gov/cicp/ /cicp/.
XV. Amendments
42 U.S.C. 247d-6d(b)(4)
The October 1, 2008, Declaration Under the Public Readiness and
Emergency Preparedness Act for Anthrax Countermeasures was first
published on October 6, 2008, and amended and republished on January 1,
2016. This is the second amendment to the Declaration.
Further amendments to this Declaration will be published in the
Federal Register.
Authority: 42 U.S.C. 247d-6d.
Xavier Becerra,
Secretary of Health and Human Services.
[FR Doc. 2022-28010 Filed 12-22-22; 8:45 am]
BILLING CODE 4150-37-P